Evidence map›Paper›PMID 41837750›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma.

Jianyu Yang, Wanhong Chen, Zonghao Duan, Minwei Yang, Lingye Tao, Yanmiao Huo, Wei Liu, Junfeng Zhang, Linli Yao, Yingbin Liu and 3 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jianyu Yang *Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-5841-5282
Wanhong Chen *Shanghai Institute of Nutrition and Health , University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.ORCID 0009-0001-0700-4878
Zonghao DuanDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-0728-5972
Minwei YangDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-9902-2183
Lingye TaoDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-8930-6302
Yanmiao HuoDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-4730-7184
Wei LiuDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0009-0000-0314-8092
Junfeng ZhangDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-8630-3090
Linli YaoState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-5025-627X
Yingbin LiuDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-6110-0185
Ping LinShanghai Institute of Nutrition and Health , University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0003-3194-5595
Hong LiShanghai Institute of Nutrition and Health , University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-5679-9980
Yongwei SunDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-5937-634X

Funding

National Natural Science Foundation of China (NSFC) 32300555National Natural Science Foundation of China (NSFC) 32470707National Natural Science Foundation of China (NSFC) 82472917National Natural Science Foundation of China (NSFC) 82473029Shanghai Sailing Program 22YF1458000
6 · The paper itself

Abstract

purposeHepatic metastasis (HM) is the leading cause of death in pancreatic ductal adenocarcinoma (PDAC). However, the underlying cellular and molecular programs remain poorly understood, leading to limited therapeutics for this disease. EXPERIMENTAL

designIn this study, we integrated single-cell RNA sequencing data from paired primary tumors and HMs, along with bulk RNA sequencing and IHC data from hundreds of patients to elucidate metastasis-associated programs.

resultsOur analysis identified a metastasis-prone malignant subpopulation, which is associated with a higher risk of HM and a transitional plastic state. This malignant subpopulation represents a poorly differentiated and highly proliferative phenotype, with H2AFZ potentially contributing to this phenomenon. Moreover, the presence of tumor cells in the liver was accompanied by an increased abundance of M2 macrophages, regulatory T cells, and exhausted T cells (Tex) in HMs compared with adjacent tissues, indicative of a shift toward an immunosuppressive environment. Notably, within the tumor environment of HMs, Tex exhibited elevated expression of PDCD1 and LAG3. The combined therapy targeting these two genes effectively inhibited tumor growth in mouse models of metastatic PDAC.

conclusionsIn conclusion, we reveal a metastasis-associated malignant subpopulation and provide a promising therapeutic strategy for metastatic PDAC.

Indexed as

Carcinoma, Pancreatic DuctalLiver NeoplasmsMyeloid CellsPancreatic NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansImmunotherapyMiceT-Cell Exhaustion

Identifiers

PMID41837750
PMCPMC13266339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.